3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Hematologic Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Melanoma
2
Lymphoproliferative Disorders
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
fludarabine phosphate
7
pembrolizumab
6
Mycophenolic Acid
6
Peripheral Blood Stem Cell Transplantation
5
Nivolumab
5
Cyclosporine
5
Cyclophosphamide
5
Whole-Body Irradiation
4
Radiotherapy
3
Busulfan
3
Antilymphocyte Serum
3
temsirolimus
2
fludarabine
2
atezolizumab
2
alectinib
2
Tacrolimus
2
Sunitinib
2
Specimen Handling
2
Paclitaxel
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
Dasatinib
2
Alemtuzumab
2
varlilumab
1
valspodar
1
utomilumab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
entrectinib
×
Lymphoid
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA